≡Menu

Category Archives: FCA Qui Tam

October 23

The SEC and Market Integrity: Safeguarding Against Fraud and Manipulation

The integrity of capital markets is paramount to supporting a fair and efficient financial landscape. Fraud and manipulation pose significant threats to the stability and fairness of these markets, potentially undermining investor confidence and economic growth. The U.S. Securities and Exchange Commission (SEC) is a pivotal institution in combating these issues, ensuring markets operate transparently and efficiently. The SEC's Mission The SEC was established in 1934 in response to the…

August 07

FCA Qui Tam

What is a Qui Tam Lawsuit?

Blowing the whistle on fraud in the workplace can be a challenging decision, especially when considering the potential for retaliation and financial repercussions. However, the significant impact of the individuals who come forward and file qui tam lawsuits cannot be overstated. That is why Miller Shah LLP is committed to helping clients navigate the complex statutory schemes designed to protect whistleblowers and ensure accountability and integrity. What Is a Qui…

August 05

FCA Qui Tam, False Claims Act, Whistleblowers

Chief Judge Goldberg Denies Appeal in Caremark Whistleblower Suit

On July 30, 2024, Chief U.S. District Judge Mitchell S. Goldberg of the Eastern District of Pennsylvania denied a request to appeal his interpretation of the Centers for Medicare and Medicaid Services' regulations from CVS Caremark Corp. ("Defendant" or "Caremark" or the "Company") in a qui tam lawsuit against the Company for falsely reporting prescription drug prices to the government in violation of the False Claims Act ("FCA"), 31 U.S.C.…

May 05

False Claims Act, FCA Qui Tam, Whistleblowers

How Does the False Claims Act Help Combat Government Fraud?

The False Claims Act (FCA) is a legal measure designed to protect the integrity of government expenditures. Enacted during the American Civil War in 1863, its primary purpose was to curb defense contractor fraud, an objective that has since broadened to encompass a range of fraudulent activities against the federal government. At Miller Shah LLP, we continue that commitment to justice by supporting whistleblowers who bring fraudulent activities to light…

August 28

False Claims Act, FCA Qui Tam, Litigation, Whistleblowers

Booz Allen Settles False Claims Act Lawsuit for $377 Million

On July 21, 2023, the Department of Justice (“DOJ”) announced that Booz Allen Hamilton Holding Corporation (“Booz Allen” or the “Company”), a Virginia-based provider of data analytics, digital solutions, and consulting services, has agreed to pay $377.45 million to resolve alleged violations of the False Claims Act, 31 U.S.C. §§ 3729–3733 (“FCA”). The settlement, one of the biggest procurement fraud settlements in DOJ history, specifically resolves allegations that Booz Allen…

July 01

Class Action, False Claims Act, FCA Qui Tam, Whistleblowers

Novartis Pays Over $642 Million to Settle FCA Allegations

On July 1, 2020, the Department of Justice (“DOJ”) announced that Novartis Pharmaceutical Corporation (“Novartis”), a New Jersey-based pharmaceutical company, agreed to pay over $642 million in separate to resolve alleged violation of the False Claims Act (“FCA”), 31 U.S.C. §§ 3729–3733. The settlement resolves allegations that Novartis made improperly payments to Medicare patients and prescribing physicians to promote Novartis's drugs, Gilenya and Afinitor. The FCA allows private citizens (known…

January 06

Class Action, False Claims Act, FCA Qui Tam, Whistleblowers

Teva Agrees to $54 Million Settlement to Resolve FCA Whistleblower Suit

On January 6, 2020, Teva Pharmaceuticals agreed to a $54 million settlement to resolve a False Claims Act action brought against Teva Pharmaceuticals USA, Inc., Teva Neuroscience, Inc., and Teva Sales and Marketing, Inc. (collectively “Teva”). The settlement resolves allegations that Teva violated the False Claims Act and the Anti-Kickback Statute by using speaker events to bribe doctors to prescribe two of its drugs, Copaxone and Azilect. The False Claims…

While this website provides general information, it does not constitute legal advice. The best way to get guidance on your specific legal issue is to contact a lawyer. To schedule a meeting with an attorney, please call 866-540-5505 or complete the intake form to email us.

Offices Throughout
the United States & Italy

Get Fort Lauderdale Directions

IT Milan

Fax number

866-540-5505

Telephone

Attorney Advertising. This information is designed for general information only. The information presented should not be construed to be formal legal advice nor the formation of a lawyer/client relationship. Past results and testimonials are not a guarantee, warranty, or prediction of the outcome of your case, and should not be construed as such. Past results cannot guarantee future performance. Any result in a single case is not meant to create an expectation of similar results in future matters because each case involves many different factors, therefore, results will differ on a case-by-case basis. By providing contact information, users acknowledge and give explicit consent to be contacted via the methods of communication provided, including SMS. Message and data rates may apply. Message frequency may vary. Reply STOP to opt out.